NAFLD vs MASLD: What actually changed in 2023?

Yes — for over 95% of patients, NAFLD and MASLD describe the same disease. The 2023 international consensus (AASLD-EASL-ALEH) renamed Non-Alcoholic Fatty Liver Disease (NAFLD) to Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD). The diagnostic criteria are slightly different — MASLD requires positive metabolic risk factors instead of just excluding alcohol — but the underlying disease is the same. A patient diagnosed with NAFLD before 2023 almost always meets MASLD criteria today.

The renaming was published in June 2023 via a multi-society Delphi consensus document (Rinella et al., Journal of Hepatology and Hepatology, 2023). It was endorsed by 236 panellists across 56 countries representing AASLD (American), EASL (European), and ALEH (Latin American) hepatology societies. Adoption in clinical practice, reports, and trials began through 2023–2024 and is now standard at most academic centres in India and globally.

MASLD = Metabolic dysfunction-Associated Steatotic Liver Disease. Each component matters: Metabolic dysfunction identifies the mechanism (insulin resistance, central obesity, dyslipidaemia, hypertension); Associated indicates causal linkage; Steatotic describes fat accumulation in liver cells (replaces "fatty" in formal terminology); Liver Disease establishes the organ and clinical context.

Yes. NASH (Non-Alcoholic Steatohepatitis) was renamed MASH (Metabolic dysfunction-Associated Steatohepatitis) in the same 2023 consensus. MASH refers to the inflammatory and fibrotic form of MASLD — the more advanced stage where liver damage is occurring, not just fat accumulation. Clinical trials like ESSENCE (semaglutide) and SYNERGY-NASH (tirzepatide) now use MASH terminology, though some retain "NASH" in trial names for historical continuity.

MetALD is a new diagnostic category created in the 2023 consensus for patients who have both metabolic dysfunction (meeting MASLD criteria) and moderate alcohol intake (140–350 g/week for females, 210–420 g/week for males). The old NAFLD framework couldn't classify these patients — they were forced into either NAFLD (incorrectly) or ALD (often inappropriately). MetALD recognises that both factors are contributing to liver damage and that treatment must address both.

Yes — your diagnosis is not invalidated. Reports written before June 2023 using "NAFLD" or "NASH" are still medically valid. They simply use the older terminology. When you have follow-up workup, the clinician may update terminology to MASLD/MASH for consistency, but the disease itself, your treatment plan, and your prognosis are unchanged. The ICD-10 codes (K76.0, K75.81) remain valid for billing and records.

Two components must be present: (1) Evidence of hepatic steatosis on imaging (ultrasound, MRI-PDFF, FibroScan with CAP score) or biopsy; AND (2) At least one of the five cardiometabolic risk factors: overweight/obesity, Type 2 diabetes or prediabetes, hypertension, elevated triglycerides, or low HDL. No exclusionary alcohol or hepatitis testing is required to confirm MASLD itself, though these are routinely checked to rule out competing diagnoses.

Yes — and this is important. The MASLD criteria explicitly recognise South Asian metabolic patterns. The BMI threshold for the overweight/obesity criterion is ≥ 23 kg/m² for South Asians (vs ≥ 25 globally), and waist circumference thresholds are also lower (≥ 90 cm for males, ≥ 80 cm for females). Indian hepatologists had been applying these lower thresholds informally for years; the 2023 consensus codifies them globally.

No — same disease, same severity grading. Disease severity is staged by liver inflammation (steatohepatitis), fibrosis grade (F0 to F4), and presence of complications — not by which name is used. The renaming is about terminology precision, not a re-classification of severity. A patient with simple steatosis (F0 fibrosis) is the same condition whether called NAFLD or MASLD.

Not retroactively — but yes on next workup. Updating old reports is unnecessary; the older terminology is medically valid. On the next consultation or follow-up workup, your clinician will typically use current MASLD/MASH nomenclature. If you have a referral to a specialist (hepatologist, transplant centre) or are entering a clinical trial, the current terminology will be used by default.

The principles remain the same; the emphasis has sharpened. Treatment still centres on weight loss, dietary change, exercise, and management of metabolic risk factors (diabetes, lipids, blood pressure). What has changed: recognition that "metabolic" disease deserves metabolic-grade interventions. GLP-1 receptor agonists (semaglutide, tirzepatide) are now squarely indicated for MASLD with metabolic syndrome — a positioning that wasn't as clean under the old NAFLD framework.

Yes — known as "lean MASLD." About 10–20% of MASLD patients have a normal BMI. The diagnosis is made when one of the other cardiometabolic criteria is met (e.g. prediabetes, hypertension, dyslipidaemia) alongside imaging evidence of liver fat. Lean MASLD is particularly common in South Asian populations, where insulin resistance and dyslipidaemia frequently appear at lower BMIs than in Western populations.

The differentiator is alcohol intake. MASLD diagnosis requires alcohol intake below 140 g/week (females) or 210 g/week (males) — roughly less than 3 standard drinks/day on average. Above the upper threshold (350 g/week females, 420 g/week males), the diagnosis is ALD (Alcohol-related Liver Disease). The middle zone — moderate metabolic disease with moderate alcohol — is the new MetALD category.